Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential

Award Number: R01EY037242
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2025
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential - Project Summary Elevated intraocular pressure (IOP) is the only modifiable risk factor of glaucoma, and all approved drugs for glaucoma aim to lower IOP but with limited efficacy to prevent retinal ganglion cell (RGC) loss. Mounting evidence suggests that both ocular hypertension (OHT) and vascular abnormalities coordinately contribute to the pathogenesis, whereas molecular mechanisms remain elusive. In the neurovascular unit (NVU), endothelial cells (ECs) and RGCs don’t have direct physical contact but are part of a complex interaction network connected via pericytes and glial cells. The daunting challenge to confirm the role of NVU dysfunction in glaucoma pathogenesis is the lack of EC-specific ligands with minimal binding to RGCs to demonstrate modulation of RGC function and survival through the NVU. To address the challenge, we recently developed an innovative technology of ligandomics to globally map cell-binding ligands with simultaneous binding activity quantification. This technology has led to the discovery of disease-restricted angiogenic factors and development of first-in- class disease-targeted anti-angiogenic therapies by our group. The objective of this project is to unequivocally confirm the contribution of the NVU to glaucoma pathogenesis and identify EC ligands with potential for neuroprotective therapy. Our central hypothesis is that OHT-restricted EC-specific ligands with undetectable binding to RGCs can mitigate or exacerbate RGC dysfunction and loss indirectly via the NVU in glaucoma. In Aim 1, we will globally map all ligands binding to OHT and healthy retinal ECs, RGCs, pericytes and glial cells with simultaneous binding activity quantification by ligandomics. Quantitative comparison of entire ligandomes will systematically identify OHT-selective EC-specific ligands with minimal binding to RGCs and glial cells. In Aim 2, OHT-selective EC-specific ligands will be independently validated their binding to NVU cells to confirm their disease binding selectivity and cell-binding specificity. In Aim 3, OHT-selective EC-specific ligands will be functionally validated for their capacity to mitigate or exacerbate RGC dysfunction and loss in glaucoma eyes. Validated EC-specific ligands capable of modulating RGC function and survival are promising targets to develop novel neuroprotective therapy with minimal side effects on healthy NVU cells. To our knowledge, ligandomics is the only omics technology to systematically identify disease-selective cell-specific ligands and is broadly applicable to all types of cells and neurological diseases with potential for transformative impact on neuroscience research and neuroprotective therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $524,973 )
2026	2026	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Vision Research	000	2	4/10/2026	NON-COMPETING CONTINUATION	$524,973
														Subtotal = $524,973

Issue Date FY: 2025 ( Subtotal = $568,122 )
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Vision Research	000	1	6/11/2025	NEW	$568,122
														Subtotal = $568,122

Grand Total All Awards = $1,093,095

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential

Award Number: R01EY037242

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2025

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer